

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. **(Currently Amended)** A human, humanized, or chimeric monoclonal antibody produced in a cell line selected for its properties of particular glycosylation of the Fc fragment of an antibody, or the glycan structure of which has been modified ex vivo, said human, humanized, or chimeric monoclonal antibody having an FcγRIII (CD16)-type ADCC rate of greater than 60%, compared with the same antibody produced in a CHO line or with a commercially available homologous antibody, wherein said human, humanized, or chimeric monoclonal antibody has an ability to induce a rate of production of at least one cytokine by the Jurkat CD16 cell or a CD16 receptor-expressing effector cell of the immune system of greater than 60%, compared with the same antibody produced in a CHO line or with a commercially available homologous antibody, and wherein said human, humanized, or chimeric monoclonal antibody is an anti-HLA-DR antibody.

2. **(Previously Presented)** The antibody as claimed in claim 1, wherein said human, humanized, or chimeric monoclonal antibody has an ADCC rate of greater than 100% at a concentration of 10 ng/ml or less, compared with the same antibody produced in a CHO line or with a commercially available homologous antibody, and a rate of production of at least one cytokine by a CD16 receptor-expressing effector cell of the immune system of greater than 1000% at a concentration of 10 ng/ml or less, compared with the same antibody produced in a CHO line or with a commercially available homologous antibody.

3-21. **(Canceled)**

22. **(Previously Presented)** The antibody as claimed in claim 1, wherein the cytokines that are released are interleukins.

23. **(Previously Presented)** The antibody as claimed in claim 1, wherein the cytokines that are released are interferons.

24. **(Previously Presented)** The antibody as claimed in claim 1, wherein the cytokines that are released are tissue necrosis factors (TNFs).

25. **(Previously Presented)** The antibody as claimed in claim 1, wherein the human, humanized, or chimeric monoclonal antibody selected has the ability to induce the secretion of at least one cytokine chosen from IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-8, TNF α , TGF β , IP10 and IFN γ , by the CD16 receptor-expressing effector cells.

26. **(Previously Presented)** The antibody as claimed in claim 1, wherein the human, humanized, or chimeric monoclonal antibody has the ability to induce the secretion of IL-2 by CD16 receptor-expressing effector cells of the immune system.

27. **(Previously Presented)** The antibody as claimed in claim 1, wherein the effector cell is a CD16 receptor-expressing Jurkat cell or a leukocytic cell or cells of the monocyte-macrophage group.

28. **(Previously Presented)** The antibody as claimed in claim 1, wherein said human, humanized, or chimeric monoclonal antibody is produced in a cell line of the rat myeloma type.

29. **(Previously Presented)** The antibody as claimed in claim 1, wherein said human, humanized, or chimeric monoclonal antibody is directed against an antigen of a pathological cell or of an organism that is pathogenic for humans, in particular against an antigen of a cancer cell.

30. **(Withdrawn)** The antibody as claimed in claim 29, wherein said antibody's specificity is to anti-Rhesus D of human red blood cells.

31. **(Canceled)**

32. **(Currently Amended)** The antibody as claimed in claim [[31]] 1, wherein said human, humanized, or chimeric monoclonal antibody has an ADCC rate of greater than 100% at a concentration of 10 ng/ml or less, and a rate of IL-2 production by a CD16-receptor-expressing effector cell of the immune system of greater than up to 1000% at a

concentration of 10 ng/ml or less, compared with the same antibody expressed in the CHO line, the expression line for apolizumab.

33. **(Currently Amended)** The antibody as claimed in claim [[31]] 1, wherein said human, humanized, or chimeric monoclonal antibody is produced in a rat myeloma line.

34. **(Withdrawn)** The antibody as claimed in claim 29, wherein said antibody is an anti-CD20.

35. **(Withdrawn)** The antibody as claimed in claim 34, wherein said antibody has an ADCC rate of greater than 100% at a concentration of 10 ng/ml or less, and a rate of IL-2 production by a CD16-receptor-expressing effector cell of the immune system of greater than up to 1000% at a concentration of 10 ng/ml or less, compared with rituximab.

36. **(Withdrawn)** The antibody as claimed in claim 34, wherein said antibody is produced in a rat myeloma line, in particular YB2/0.

37. **(Withdrawn)** The antibody as claimed in claim 29, wherein said antibody is selected from anti-Ep-CAM, anti-KIR3DL2, anti-VEGFR, anti-HER1, anti-HER2, anti-GD, anti-GD2, anti-GD3, anti-CD23, anti-CD30, anti-CD33, anti-CD38, anti-CD44, anti-CD52, anti-CA125 and anti-ProteinC; anti-Ep-CAM, anti-HER2, anti-CD52, anti-HER1, anti-GD3, anti-CA125 anti-GD, anti-GD2, anti-CD23 and anti-ProteinC; antivirals: HBV, HCV, HIV and RSV, anti-idiotypes specific for inhibitors, for example for clotting factors including FVIII and FIX.

38. **(Previously Presented)** The antibody as claimed in claim 1, wherein said human, humanized, or chimeric monoclonal antibody has an ability to induce a rate of production of at least one cytokine by the Jurkat CD16 cell or a CD16 receptor-expressing effector cell of the immune system of greater than 100%, compared with the same antibody produced in a CHO line or with a commercially available homologous antibody.

39. **(Previously Presented)** The antibody as claimed in claim 1, wherein said human, humanized, or chimeric monoclonal antibody has an ability to induce a rate of production of at least one cytokine by the Jurkat CD16 cell or a CD16 receptor-expressing

effector cell of the immune system of greater than 200%, compared with the same antibody produced in a CHO line or with a commercially available homologous antibody.

40. **(Previously Presented)** The antibody as claimed in claim 1, wherein said human, humanized, or chimeric monoclonal antibody has an FcγRIII (CD16)-type ADCC rate of greater than 70%, compared with the same antibody produced in a CHO line or with a commercially available homologous antibody.

41. **(Previously Presented)** The antibody as claimed in claim 1, wherein said human, humanized, or chimeric monoclonal antibody has an FcγRIII (CD16)-type ADCC rate of greater than 80%, compared with the same antibody produced in a CHO line or with a commercially available homologous antibody.

42. **(Previously Presented)** The antibody as claimed in claim 1, wherein said human, humanized, or chimeric monoclonal antibody has an FcγRIII (CD16)-type ADCC rate of greater than 90%, compared with the same antibody produced in a CHO line or with a commercially available homologous antibody.

43. **(Previously Presented)** The antibody as claimed in claim 27, wherein the effector cell is a leukocytic cell of the NK (natural killer) family.

44. **(Previously Presented)** The antibody as claimed in claim 28, wherein said human, humanized, or chimeric monoclonal antibody is produced in a YB2/0 cell line.

45. **(Previously Presented)** The antibody as claimed in claim 33, wherein said human, humanized, or chimeric monoclonal antibody is produced in a YB2/0 cell line.